Plerixafor
Subjects received MRG-001 on day 1, 3 and 5. Plerixafor PK was evaluated after a subject received a single dose on day 1 and after the last dose administration on day 5. The mean plasma concentration-time profiles of plerixafor increased with dose on day 1 and day 5. The elimination appeared to be monophasic for all three doses after dosing on day 1 and day 5. One treated subject had an aberrant value (BLQ) at 3 h after the dose on day 1 for plerixafor. As this sample was at the potential time to maximum plasma concentration (TPlasma PK parameters for plerixafor following SC administration of MRG-001 on day 1 and day 5 are summarized in MRG-001 pharmacokinetics(A) Time profiles for plerixafor following SC administration of a single dose of 0.005, 0.01, and 0.02 mL/kg MRG-001 on day 1.(B) Time profiles for plerixafor following SC administration of 0.005, 0.01, and 0.02 mL/kg MRG-001 on day 5.(C) Time profiles for tacrolimus following SC administration of a single dose of 0.005, 0.01, and 0.02 mL/kg MRG-001 on day 1.(D) Time profiles for tacrolimus following SC administration of 0.005, 0.01, and 0.02 mL/kg MRG-001 on day 5. n = 4 per group.Bars represent standard deviation of the mean.The geometric mean C